Monograph Details
|
|
Infections & Infestations
> Viral infections
|
|
ISENTRESS |
| Manufacturer |
|
Merck & Co., Inc. |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
HIV-1 integrase strand transfer inhibitor. |
| Generic Name |
|
Raltegravir (as potassium) 400mg; tabs. |
| Indications |
|
HIV-1 infection, in combination with other antiretrovirals, in treatment-experienced adults with evidence of viral replication and HIV-1 strains resistant to multiple antiretrovirals. |
| Children |
|
<16yrs: not recommended. |
| Adults |
|
>16yrs: 400mg twice daily. Avoid dosing before dialysis sessions. |
| Precautions |
|
Severe hepatic impairment. Monitor for immune reconstitution syndrome (esp. during initial therapy), myopathy, rhabdomyolysis. Pregnancy (Cat.C). Nursing mothers: not recommended. |
| Interactions |
|
Antagonized by rifampin, possibly other strong UGT1A1 inducers. May be potentiated by UGT1A1 inhibitors. Caution with other drugs that can cause myopathy (eg, statins). |
| Adverse Reactions |
|
Nausea, headache, diarrhea, pyrexia; others (see literature). |
| Extra Text |
|
Note: Register pregnant patients exposed to raltegravir by calling (800) 258-4263. |
| How Supplied |
|
Tabs—60 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
